New cancer drug combo tested in early human trial

NCT ID NCT05763004

Completed Disease control Sponsor: ImmunOs Therapeutics AG Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Researchers also looked for early signs of tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IOS-1002 (an experimental drug) and pembrolizumab (a cancer immunotherapy)
What this could lead to: If it works, this could point toward a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 47 participants, so safety and dosing are the main focus—not yet proof of effectiveness. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

Alfread Health

Melbourne, Australia
Austin Health / Cancer Clinical Trials Center

Heidelberg, Australia
Linear Clinical Research

Perth, Australia
Monash Health Medical Center

Clayton, Australia
Peter MacCallum Cancer Center

Melbourne, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.